StriVectin Awarded for Development of Niacin Molecule that Promotes DNA Repair and May Help Prevent Skin Cancer

StriVectin was one of three honorees to receive The Skin Cancer Foundation's 2011 Skin Sense Awards at the Foundation’s annual fundraising gala in New York earlier this month. The award is given for exceptional achievement in skin health, including public education about sun protection and skin cancer prevention.

StriVectin was recognized for development of its exclusive NIA-114™ (Niacin-derived Myristyl Nicotinate) technology, the result of 30 years of research into DNA repair and skin cancer prevention. NIA-114™ is found in several of StriVectin’s latest product releases, including StriVectin-SD Intensive Concentrate for Stretch Marks and Wrinkles and StriVectin-TL tightening products.

In accepting the award, StriVectin CEO Melisse Shaban said, "Our mission is to repair and rebuild healthy skin layers, because our belief is that healthy skin is truly the most beautiful skin."

NIA-114™ has been chosen by the National Cancer Institute for further study as a possible skin cancer prevention agent.

Other honorees were:

• Bristol-Myers Squibb for development of Yervoy (called ipilimumab during its experimental phase), the first new therapy approved for the treatment of advanced melanoma in more than 13 years; and

• The Skin Cancer Foundation’s Photobiology Committee, an independent volunteer panel of top experts on sun damage and sun protection, for their efforts to educate the public regarding "junk science" being promulgated by the Environmental Working Group against sunscreen use.

Tags: anti-aging skincare, StriVectin honored, 2011 Skin Sense Awards, advances in skincare, effective anti-aging skincare ingredients, StriVectin research, NIA-114 by StriVectin, advances in anti-aging